Opinions
Robert McWhirter
Cardiol Therapeutics
CRDL-T
HOLD
Feb 15, 2019
He has met management twice and they had their IPO in mid-December. They have looked into the use of CBD to use as an anti-inflammatory for heart patients. They are working on developing synthetic CBD. They think they could produce 1 millions grams of CBD this year. This creates a great opportunity and they have enough technology to advance their strategy. If they can sell the CBC, the company is fairly valued.
$6.620
Stock price when the opinion was issued
biotechnology
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
BUY
COVID-19 heart issues? The company makes a synthetic CBD. Their original work saw CBD helped to reduce inflammation of the heart. It is expected they will start to re-purpose their product for COVID patients. This would help accelerate testing by about 2 years. This could lead to product being sold in Canada very quickly. A great opportunity.
biotechnology